ITAT Ahmedabad ruled that a notice under section 148 issued beyond the statutory period is invalid, quashing a ₹115 crore reassessment of a share-trading company. The Tribunal emphasized adherence to ...

Flight reductions across 40 major airports nationwide will end Monday morning. Treasury Secretary Scott Bessent said Sunday that Americans will begin to feel the White House's efforts to rein in the ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention that ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant ...

The "Epilepsy Therapeutics Market With Impact Analysis of US Tariffs (2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

Aston University's Dr Jonathan Cox and New Zealand Mānuka honey company Comvita have announced a significant milestone in their three-year research collaboration, with the filing of a new patent for a ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world ...

Celltrion announced that the European Commission (EC) has granted marketing authorization for Remsima IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab.

Merus N.V., an oncology company developing full-length multispecific antibodies and antibody drug conjugates, and Halozyme Therapeutics Inc., a biopharmaceutical company advancing subcutaneous drug ...

- ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 ...

- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly ...